This episode explores the extraordinary and ethically complex journey of Celgene, a pharmaceutical company that transformed one of history's most infamous drugs—thalidomide—into a medical breakthrough for cancer patients. Once synonymous with tragedy due to its devastating effects as a teratogen in the 1950s and 60s, thalidomide was quietly resurrected by Celgene in the 1990s after scientists discovered its potential to inhibit angiogenesis, effectively starving tumors of blood supply. Despite the drug’s dark legacy, Celgene secured FDA approval under strict conditions in 1998 for treating leprosy, but it was off-label use for multiple myeloma that sparked a medical revolution. As patient demand surged, so did the price, raising urgent ethical concerns about access and affordability. The company followed up with Revlimid, a safer, more potent derivative that became a blockbuster drug, generating billions annually. Celgene’s aggressive patent strategies, legal battles, and eventual acquisition by Bristol-Myers Squibb for $74 billion further illustrate the high-stakes world of pharmaceutical innovation. The story also highlights deeply personal accounts, such as Maria, whose father lived nearly a decade longer thanks to thalidomide-based treatment, witnessing key life milestones he would have otherwise missed. While Celgene’s contributions to immuno-oncology and CAR-T cell therapy have reshaped modern cancer care, the company’s legacy remains entangled with questions of corporate ethics, pricing practices, and the human cost of medical progress. This is a tale of redemption and reckoning, where scientific brilliance collides with economic realities, leaving society to grapple with how we value life, innovation, and the companies that hold the keys to survival.